Gradman T J, Laws A, Thompson L W, Reaven G M
Department of Medicine, Stanford University School of Medicine, California.
J Am Geriatr Soc. 1993 Dec;41(12):1305-12. doi: 10.1111/j.1532-5415.1993.tb06480.x.
To determine whether cognitive function improves with improved glycemic control in older subjects with non-insulin-dependent diabetes (NIDDM). We hypothesized that with improved glycemic control: 1) learning and memory, 2) attention, and 3) complex perceptual-motor function would improve, but that 4) simple perceptual-motor function would not.
Non-randomized control trial.
Aging Study Unit, Department of Veterans Affairs Medical Center.
Thirty subjects with NIDDM; 17 on oral hypoglycemic agents; 13 untreated at study entry. Thirteen normal controls.
Subjects on oral hypoglycemic agents were taken off medications. After 1 month, they and previously untreated subjects began treatment with glipizide. Dose was titrated up weekly until fasting plasma glucose was less than 7.8 mmol/L or maximal dose (40 mg/day). Controls received no medication.
Fasting plasma glucose (FPG), glycated hemoglobin, and measures of cognitive function in four general categories: 1) learning and memory, 2) ability to sustain attention, 3) complex perceptual-motor function, and 4) simple perceptual-motor function. All were evaluated in subjects with NIDDM at baseline (T1), after 1-month washout (T2), and after 2 (T3) and 4 months (T4) of optimal glycemic control or maximal dose. Controls were evaluated at the same intervals.
FPG and glycated hemoglobin rose in previously treated subjects from T1 to T2 (9.4 +/- SEM 0.4 to 14.7 +/- 0.7 mmol/L and 10.9 +/- 0.7% to 12.2 +/- 0.6%, respectively) but were unchanged in previously untreated subjects (11.3 +/- 0.6 to 11.8 +/- 0.9 mmol/L and 10.9 +/- 0.7% to 11.7 +/- 0.7%). With glipizide treatment, there was a decrease in FPG level at T3 (9.4 +/- 0.5 mmol/L in previously treated, 6.9 +/- 0.4 mmol/L in previously untreated), which persisted at T4. Glycated hemoglobin fell similarly. FPG and glycated hemoglobin were unchanged in controls. As hypothesized, learning and memory improved over time with treatment in both groups of subjects but was unchanged in controls (P < 0.05). Detailed analysis indicated that the improvement occurred primarily in the learning of verbal material. Contrary to hypothesis, attention and complex perceptual-motor function did not show improvement. As expected, simple perceptual-motor function did not show any improvement with treatment.
The results are consistent with previous findings that poor glycemic control in older subjects with NIDDM is associated with decreased cognitive functioning, and suggest that verbal learning and memory may improve with improved glycemic control.
确定在非胰岛素依赖型糖尿病(NIDDM)老年患者中,血糖控制改善是否会使认知功能得到改善。我们假设随着血糖控制的改善:1)学习和记忆,2)注意力,以及3)复杂的感知运动功能会得到改善,但4)简单的感知运动功能不会改善。
非随机对照试验。
退伍军人事务医疗中心老年研究室。
30例NIDDM患者;17例服用口服降糖药;13例在研究开始时未接受治疗。13例正常对照者。
服用口服降糖药的患者停用药物。1个月后,他们和之前未接受治疗的患者开始使用格列吡嗪治疗。剂量每周递增,直至空腹血糖低于7.8 mmol/L或达到最大剂量(40 mg/天)。对照组不服用药物。
空腹血糖(FPG)、糖化血红蛋白,以及四个一般类别的认知功能指标:1)学习和记忆,2)维持注意力的能力,3)复杂的感知运动功能,4)简单的感知运动功能。所有指标均在NIDDM患者基线时(T1)、1个月洗脱期后(T2)、最佳血糖控制或最大剂量治疗2个月(T3)和4个月(T4)后进行评估。对照组在相同时间间隔进行评估。
之前接受治疗的患者从T1到T2时FPG和糖化血红蛋白升高(分别从9.4±标准误0.4 mmol/L升至14.7±0.7 mmol/L,从10.9±0.7%升至12.2±0.6%),但之前未接受治疗的患者则无变化(从11.3±0.6 mmol/L升至11.8±0.9 mmol/L,从10.9±0.7%升至11.7±0.7%)。使用格列吡嗪治疗后,T3时FPG水平下降(之前接受治疗的患者为9.4±0.5 mmol/L,之前未接受治疗的患者为6.9±0.4 mmol/L),并在T4时持续下降。糖化血红蛋白也有类似下降。对照组的FPG和糖化血红蛋白无变化。如假设的那样,两组患者的学习和记忆随着治疗时间的推移均有改善,但对照组无变化(P<0.05)。详细分析表明,改善主要发生在语言材料的学习方面。与假设相反,注意力和复杂的感知运动功能未显示出改善。正如预期的那样,简单的感知运动功能在治疗后未显示出任何改善。
这些结果与之前的研究结果一致,即NIDDM老年患者血糖控制不佳与认知功能下降有关,并表明血糖控制改善可能会使语言学习和记忆得到改善。